25
Participants
Start Date
October 23, 2017
Primary Completion Date
August 19, 2019
Study Completion Date
August 19, 2019
SHP615
SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Yamanashi Prefectural Central Hospital, Kofu
Gifu Prefectural General Medical Center, Gifu
Hokkaido University Hospital, Sapporo
Tokyo Women's Medical University Hospital, Tokyo
NHO Minami-Okayama Medical Center, Okayama
Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo
Jichi Children's Medical Center Tochigi, Saitama-shi
Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
Fukuoka Children's Hospital(NW), Fukuoka
NHO Hokkaido Medical Center, Hokkaidō
Kumamoto Saishunso National Hospital, Kumamoto
NHO Nagasaki Medical Center, Nagasaki
NHO Nishi Niigata Chuo National Hospital, Niigata
Okayama University Hospital, Okayama
Nakano Children's Hospital, Osaka
Osaka Women's and Children's Hospital(NW), Osaka
Aichi Children's Health and Medical Center(NW), Ōbu
Saitama Children's Medical Center(NW), Saitama
Osaka University Hospital, Suita
Osaka University Hospital, Yamadaoka
National Center Hospital, NCNP, Tokyo
Tottori University Hospital, Tottori
Kanagawa Children's Medical Center(NW), Yokohama
Lead Sponsor
Shire
INDUSTRY